Next Article in Journal
Diving through Membranes: Molecular Cunning to Enforce the Endosomal Escape of Antibody-Targeted Anti-Tumor Toxins
Next Article in Special Issue
Single Domain Antibody Fragments as Drug Surrogates Targeting Protein–Protein Interactions inside Cells
Previous Article in Journal / Special Issue
Isolation of Panels of Llama Single-Domain Antibody Fragments Binding All Nine Neuraminidase Subtypes of Influenza A Virus
Antibodies 2013, 2(2), 193-208; doi:10.3390/antib2020193
Review

In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments

1,2,3,* , 1,2 and 1,2,*
1 Genetics and Development Division, Toronto Western Research Institute, MCL-6-415, 399 Bathurst Street, Toronto M5T 2S8, Ontario, Canada 2 Department of Physiology, Faculty of Medicine, University of Toronto, Toronto M5S 1A8, Ontario, Canada 3 Department of Ophthalmology, Faculty of Medicine, University of Toronto, Toronto M5S 1A8, Ontario, Canada
* Authors to whom correspondence should be addressed.
Received: 4 February 2013 / Revised: 25 March 2013 / Accepted: 29 March 2013 / Published: 11 April 2013
(This article belongs to the Special Issue Single-Domain Antibody)
View Full-Text   |   Download PDF [397 KB, uploaded 11 April 2013]   |   Browse Figures

Abstract

Single chain variable domain (Fv) fragments (scFv) are powerful tools in research and clinical settings, owing to better pharmacokinetic properties compared to the parent monoclonal antibodies and the relative ease of producing them in large quantities, at low cost. Though they offer several advantages, they suffer from lower binding affinity and rapid clearance from circulation, which limits their therapeutic potential. However, these fragments can be genetically modified to enhance desirable properties, such as multivalency, high target retention and slower blood clearance, and as such, a variety of scFv formats have been generated. ScFvs can be administered by systemic injection for diagnostic and therapeutic purposes. They can be expressed in vivo through viral vectors in instances where large infection rates and sustenance of high levels of the antibody is required. ScFvs have found applications as tools for in vivo loss-of-function studies and inactivation of specific protein domains, diagnostic imaging, tumor therapy and treatment for neurodegenerative and infectious diseases. This review will focus on their in vivo applications.
Keywords: scFv; recombinant antibodies; in vivo expression; adeno-associated virus (AAV); immunotherapy scFv; recombinant antibodies; in vivo expression; adeno-associated virus (AAV); immunotherapy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote
MDPI and ACS Style

Monnier, P.P.; Vigouroux, R.J.; Tassew, N.G. In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments. Antibodies 2013, 2, 193-208.

View more citation formats

Related Articles

Article Metrics

Comments

Cited By

[Return to top]
Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert